Why is Summit Therapeutics stock plunging today?

Summit Therapeutics (SMMT) stock fell 17.5% to $11.68 after the FDA issued a Complete Response Letter for its lung cancer treatment, citing insufficient overall survival data. Analysts had mixed reactions, with Jefferies seeing limited downside and Barclays lowering its price target to $18. The company remains committed to the drug's development. The Nasdaq was down 0.9%, adding to market pressure.

Original reporting
Published Nov 16, 2026, 10:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$SMMT
Bearish
high confidence
Mentioned
$SMMT
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The regulatory denial removes the primary catalyst for near‑term revenue, prompting a sell‑side reaction and heightened volatility.

02

Market read

The news directly drives a 17.5% drop in Summit's stock, with potential spill‑over to other biotech names awaiting FDA decisions.

03

What to watch

Potential partnership or licensing deals for ivonescimab could mitigate the impact of the CRL.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Summit Therapeutics announced a Complete Response Letter from the FDA for its ivonescimab BLA, leading to a sharp pre‑market sell‑off.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

FDA issued a Complete Response Letter rejecting Summit Therapeutics' BLA for ivonescimab, causing a 17.5% pre‑market drop.

Expected impact

likely continued decline as investors reassess the regulatory pathway.

Evidence & confidence

The CRL is a material regulatory setback for a biotech with a flagship asset; the stock already fell 17.5% pre‑open.

Market effects

Biotech sector may see broader risk aversion after a high‑profile FDA denial.

US Nasdaq likely pressured by the drop in a biotech name.

Limited to investors tracking FDA outcomes; no immediate global macro effect.

Counterpoint

If Summit can secure additional data to address overall survival, the stock may rebound on a later positive readout.

Key entities

  • Summit Therapeutics

    Biopharma developing ivonescimab for NSCLC.

  • FDA

    U.S. Food and Drug Administration issuing the CRL.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.

$SMMTHighAI 9/10

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.

$SMMTHighAI 8/10

SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.